Payment overview · 2025
General Payments
$4,591.79
134 reported records · 38 companies
Healthcare provider profile · identity verified
Roman B Malley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRESNO, CA · NPI 1083655443
Verified facts
What the public records show
CMS Open Payments records show Roman B Malley, MD received $4,591.79 in general payments during 2025 across 134 reported records.
Amgen Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 430 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $863.16 | 18.8% | 44 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $460.00 | 10.0% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $305.41 | 6.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $298.30 | 6.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $296.60 | 6.5% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $244.35 | 5.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $205.42 | 4.5% | 11 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $185.73 | 4.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $172.39 | 3.8% | 3 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $171.97 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $147.17 | 3.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $146.15 | 3.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $138.54 | 3.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $122.77 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.84 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $79.27 | 1.7% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.79 | 1.3% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.81 | 1.2% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $43.84 | 0.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.74 | 0.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.10 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.03 | 0.7% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $27.18 | 0.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.47 | 0.6% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $25.82 | 0.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.30 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.98 | 0.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $24.81 | 0.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.67 | 0.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $24.22 | 0.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.85 | 0.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.79 | 0.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.75 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.76 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.61 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.53 | 0.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.42 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,591.79 | 134 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $635.83 | 38 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $288.31 | 35 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $258.37 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $249.99 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $227.33 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $213.54 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $185.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $172.39 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.03 | 3 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $171.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.15 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $147.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $146.71 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $146.15 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $138.54 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $137.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $125.17 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $125.17 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $125.17 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $122.77 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $100.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $82.77 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $81.62 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.25 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $79.27 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $79.27 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.01 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $60.79 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $54.81 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.59 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 430 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 174 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
100 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
109 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
430 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2534 | 304 |
| Amlodipine Besylate | Amlodipine Besylate | 1208 | 147 |
| Metformin Hcl | Metformin Hcl | 1049 | 116 |
| Gabapentin | Gabapentin | 867 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 818 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 770 | 71 |
| Furosemide | Furosemide | 704 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 697 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 652 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 541 | 28 |
| Lisinopril | Lisinopril | 488 | 70 |
| Donepezil Hcl | Donepezil Hcl | 430 | 26 |
| Eliquis | Apixaban | 430 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 402 | 72 |
| Carvedilol | Carvedilol | 393 | 49 |
| Allopurinol | Allopurinol | 392 | 46 |
| Alendronate Sodium | Alendronate Sodium | 376 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 374 | 104 |
| Losartan Potassium | Losartan Potassium | 360 | 66 |
| Omeprazole | Omeprazole | 339 | 44 |
| Divalproex Sodium | Divalproex Sodium | 335 | 26 |
| Baclofen | Baclofen | 329 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 320 | 19 |
| Ezetimibe | Ezetimibe | 312 | 77 |
| Levetiracetam | Levetiracetam | 279 | 18 |
| Montelukast Sodium | Montelukast Sodium | 267 | 28 |
| Trazodone Hcl | Trazodone Hcl | 265 | 27 |
| Finasteride | Finasteride | 249 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 241 | 40 |
| Potassium Chloride | Potassium Chloride | 240 | 40 |
| Glipizide | Glipizide | 230 | 37 |
| Memantine Hcl | Memantine Hcl | 227 | 21 |
| Olanzapine | Olanzapine | 218 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 204 | 32 |
| Famotidine | Famotidine | 196 | 36 |
| Spironolactone | Spironolactone | 196 | 20 |
| Buspirone Hcl | Buspirone Hcl | 191 | 30 |
| Jardiance | Empagliflozin | 174 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 166 | 20 |
| Sertraline Hcl | Sertraline Hcl | 146 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 21 |
| Azelastine Hcl | Azelastine Hcl | 130 | 50 |
| Pregabalin | Pregabalin | 128 | 29 |
| Simvastatin | Simvastatin | 126 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 24 |
| Mirtazapine | Mirtazapine | 118 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 16 |
| Risperidone | Risperidone | 113 | suppressed |
| Clozapine | Clozapine | 112 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 112 | 29 |
| Lamotrigine | Lamotrigine | 110 | suppressed |
| Trulicity | Dulaglutide | 109 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 32 |
| Linzess | Linaclotide | 100 | 12 |
| Fenofibrate | Fenofibrate | 98 | 13 |
| Movantik | Naloxegol Oxalate | 97 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 32 |
| Alprazolam | Alprazolam | 92 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 22 |
| Latanoprost | Latanoprost | 87 | 20 |
| Nifedipine Er | Nifedipine | 85 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 12 |
| Clonidine Hcl | Clonidine Hcl | 83 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 24 |
| Midodrine Hcl | Midodrine Hcl | 83 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 12 |
| Propranolol Hcl | Propranolol Hcl | 80 | suppressed |
| Valsartan | Valsartan | 78 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 76 | suppressed |
| Xarelto | Rivaroxaban | 76 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 21 |
| Haloperidol | Haloperidol | 75 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 74 | suppressed |
| Lactulose | Lactulose | 74 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 73 | suppressed |
| Lovastatin | Lovastatin | 73 | suppressed |
| Ozempic | Semaglutide | 73 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 70 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 67 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 64 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 63 | 27 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 59 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 13 |
| Atenolol | Atenolol | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 53 | suppressed |
| Dapsone | Dapsone | 52 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 19 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Lithium Carbonate | Lithium Carbonate | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Entacapone | Entacapone | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Hydroxyurea | Hydroxyurea | 44 | suppressed |
| Lorazepam | Lorazepam | 44 | 12 |
| Roflumilast | Roflumilast | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 30 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Prednisone | Prednisone | 42 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Cephalexin | Cephalexin | 39 | 33 |
| Lubiprostone | Lubiprostone | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Folic Acid | Folic Acid | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Insulin Lispro | Insulin Lispro | 33 | suppressed |
| Nystatin | Nystatin | 33 | 15 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Daptomycin | Daptomycin | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 27 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Naproxen | Naproxen | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 16 |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 23 | suppressed |
| Permethrin | Permethrin | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Alphagan P | Brimonidine Tartrate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | 11 |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Niacin Er | Niacin | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,591.79 · 134 records | Amgen Inc. | ABRYSVO, AFREZZA, AIRSUPRA, AMVUTTRA, APTIMA, AREXVY, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fintepla, Fluad, Flucelvax, GARDASIL 9, Heplisav-B, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LEQEMBI, LEQVIO, LYBALVI, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OMVOH, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, UROLIFT, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error